Post-therapeutic relapse of psoriasis after CD11a blockade is associated with T cells and inflammatory myeloid DCs
Leanne M Johnson-Huang, Cara A Pensabene, Kejal R Shah, Katherine C Pierson, Toyoko Kikuchi, Tim Lentini, Patricia Gilleaudeau, Mary Sullivan-Whalen, Inna Cueto, Artemis Khatcherian, Luke A Hyder, Mayte Suárez-Fariñas, James G Krueger, Michelle A Lowes, Leanne M Johnson-Huang, Cara A Pensabene, Kejal R Shah, Katherine C Pierson, Toyoko Kikuchi, Tim Lentini, Patricia Gilleaudeau, Mary Sullivan-Whalen, Inna Cueto, Artemis Khatcherian, Luke A Hyder, Mayte Suárez-Fariñas, James G Krueger, Michelle A Lowes
Abstract
To understand the development of new psoriasis lesions, we studied a group of moderate-to-severe psoriasis patients who experienced a relapse after ceasing efalizumab (anti-CD11a, Raptiva, Genentech). There were increased CD3(+) T cells, neutrophils, CD11c(+) and CD83(+) myeloid dendritic cells (DCs), but no increase in CD1c(+) resident myeloid DCs. In relapsed lesions, there were many CD11c(+)CD1c(-), inflammatory myeloid DCs identified by TNFSF10/TRAIL, TNF, and iNOS. CD11c(+) cells in relapsed lesions co-expressed CD14 and CD16 in situ. Efalizumab induced an improvement in many psoriasis genes, and during relapse, the majority of these genes reversed back to a lesional state. Gene Set Enrichment Analysis (GSEA) of the transcriptome of relapsed tissue showed that many of the gene sets known to be present in psoriasis were also highly enriched in relapse. Hence, on ceasing efalizumab, T cells and myeloid cells rapidly enter the skin to cause classic psoriasis.
Trial registration: Clinicaltrials.gov NCT00115076.
Conflict of interest statement
Competing Interests: The authors have read the journal's policy and have the following conflicts: JGK has served as a consultant for Genentech, who provided efalizumab for the clinical trial. This does not alter the authors's adherence to all the PLoS ONE policies on sharing data and materials. Other authors declare that they have no competing interests related to this work.
Figures
References
- Vugmeyster Y, Kikuchi T, Lowes MA, Chamian F, Kagen M, et al. Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol. 2004;113:38–46.
- Guttman-Yassky E, Vugmeyster Y, Lowes MA, Chamian F, Kikuchi T, et al. Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness. J Invest Dermatol. 2008;128:1182–1191.
- Krueger JG, Ochs HD, Patel P, Gilkerson E, Guttman-Yassky E, et al. Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study. J Invest Dermatol. 2008;128:2615–2624.
- Pugashetti R, Koo J. Efalizumab discontinuation: a practical strategy. J Dermatolog Treat. 2009;20:132–136.
- Gordon KB, Feldman SR, Koo JY, Menter A, Rolstad T, et al. Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol. 2005;141:82–84.
- Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol. 2006;54:S171–181.
- Seminara NM, Gelfand JM. Assessing long-term drug safety: lessons (re) learned from raptiva. Semin Cutan Med Surg. 2010;29:16–19.
- Kothary N, Diak IL, Brinker A, Bezabeh S, Avigan M, et al. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 2011
- Fuentes-Duculan J, Suárez-Fariñas M, Zaba LC, Nograles KE, Pierson KC, et al. A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J Invest Dermatol. 2010;130:2412–2422.
- Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Farinas MS, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204:3183–3194.
- Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, Zaba LC, Cardinale I, et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol. 2008;181:7420–7427.
- Suarez-Farinas M, Pellegrino M, Wittkowski KM, Magnasco MO. Harshlight: a “corrective make-up” program for microarray chips. BMC Bioinformatics. 2005;6:294.
- Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A. 2005;102:2075–2080.
- Zaba LC, Fuentes-Duculan J, Steinman RM, Krueger JG, Lowes MA. Normal human dermis contains distinct populations of CD11cBDCA-1 dendritic cells and CD163FXIIIA macrophages. J Clin Invest. 2007;117:2517–2525.
- Johnson-Huang LM, Suarez-Farinas M, Sullivan-Whalen M, Gilleaudeau P, Krueger JG, et al. Effective Narrow-Band UVB Radiation Therapy Suppresses the IL-23/IL-17 Axis in Normalized Psoriasis Plaques. J Invest Dermatol 2010
- Lowes MA, Chamian F, Abello MV, Fuentes-Duculan J, Lin SL, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A. 2005;102:19057–19062.
- Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I, et al. Psoriasis Is Characterized by Accumulation of Immunostimulatory and Th1/Th17 Cell-Polarizing Myeloid Dendritic Cells. J Invest Dermatol. 2009;129:79–88.
- Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Johnson-Huang LM, Nograles KE, et al. Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. J Allergy Clin Immunol. 2010;125:1261–1268 e1269.
- Serbina NV, Salazar-Mather TP, Biron CA, Kuziel WA, Pamer EG. TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity. 2003;19:59–70.
- Suárez-Fariñas M, Lowes MA, Zaba LC, Krueger JG. Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA). PLoS One. 2010;5:e10247.
- Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, Suarez-Farinas M, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159:1086–1091.
- Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, Nograles KE, Tian S, et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. Journal of Investigative Dermatology. 2011;131:677–687.
- Mee JB, Cork MJ, di Giovine FS, Duff GW, Groves RW. Interleukin-1: a key inflammatory mediator in psoriasis? Cytokine. 2006;33:72–78.
- Guttman-Yassky E, Suarez-Farinas M, Chiricozzi A, Nograles KE, Shemer A, et al. Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J Allergy Clin Immunol. 2009;124:1235–1244 e1258.
- Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866–873.
- Lowes MA, Turton JA, Krueger JG, Barnetson RS. Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series. BMC Dermatol. 2005;5:9.
- Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell. 2001;106:259–262.
- Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Aphale A, et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol. 2008;181:4733–4741.
- Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol. 2009;27:669–692.
- Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity. 2008;29:497–510.
- Serbina NV, Kuziel W, Flavell R, Akira S, Rollins B, et al. Sequential MyD88-independent and -dependent activation of innate immune responses to intracellular bacterial infection. Immunity. 2003;19:891–901.
- Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, et al. Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis. J Invest Dermatol 2009
- Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 2003;14:409–426.
- Capsoni F, Ongari AM, Frigerio E, Taglioni M, Altomare GF. Effect of Efalizumab on neutrophil and monocyte functions in patients with psoriasis. Int J Immunopathol Pharmacol. 2008;21:437–445.
Source: PubMed